Qiagen N.V.: Why This Quiet Biotech Stock Just Got Loud for US Investors
Qiagen N.V., a Netherlands-based biotech tools company with a strong US presence, is gaining attention for its role in diagnostics, cancer testing, and infectious disease labs. While not a meme stock, recent analyst updates and commentary highlight its stable cash flows, recurring consumables revenue, and AI-driven lab automation, positioning it as a long-term diagnostics and lab infrastructure play. The company's US-listed shares (QGEN) make it directly accessible to American investors looking for a defensive health-tech investment.
New Evercode v4 lets labs profile 5M cells, recover 75% more
Parse Biosciences, a QIAGEN company, has launched its new Evercode™ Whole Transcriptome v4 product line, which offers expanded scalability of up to five million cells and 384 samples in a single run. This new chemistry enhances gene detection per cell, reduces sequencing costs, and increases cell recovery by up to 75% through a simplified magnetic bead-based workflow. The Evercode v4 is designed to make single-cell RNA sequencing more accessible and efficient for researchers, enabling higher biological resolution.
Stifel Maintains Qiagen NV(QGEN.US) With Hold Rating, Raises Target Price to $50
Stifel analyst Daniel Arias has reiterated a "Hold" rating for Qiagen NV (QGEN.US) and increased the target price from $47.37 to $50. This decision is based on TipRanks data, which indicates a 45.7% success rate and a 0.0% average return for the analyst over the past year. The information provided is for informational purposes only and not investment advice.
BlackRock Discloses 10.68% Capital Interest and 11.8% Voting Stake in Qiagen
BlackRock, Inc. has revealed a substantial shareholding in Qiagen, holding a 10.68% capital interest and 11.80% of voting rights through various subsidiaries and instruments as of February 11, 2026. This significant stake, largely indirect, underscores strong institutional investor interest in Qiagen's equity and hints at BlackRock's potential influence on the company's governance. Qiagen (QGEN) specializes in sample and assay technologies for molecular diagnostics and currently has a Hold rating from analysts with a $50.00 price target.
Qiagen discloses executive share-based compensation transaction
Qiagen disclosed that executive Thierry Bernard received 7,650 Performance Stock Units from a 2016 grant which vested on February 15, 2026. After a net share settlement for taxes, Bernard obtained 3,856 common shares, demonstrating the company's continued use of equity-based compensation to align management and shareholder interests. Qiagen (QGEN) maintains a Hold rating from analysts with a $50.00 price target, highlighting its role as a key player in the life sciences sector.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, as informed by the AFM. The notification details transactions on February 11, 2026, by BlackRock, Inc., showing their significant holdings in QIAGEN N.V., including both real and potential voting rights from various BlackRock entities. The total capital interest for BlackRock, Inc. is 10.68%, and total voting rights are 11.80%.
PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR
This article details a manager's transaction at QIAGEN N.V., specifically Thierry Bernard, a member of the managing body. The announcement concerns the release of 7,650 Performance Stock Units on February 15, 2026, based on a grant from 2016, leading to the receipt of 3,856 common shares after net share settlement for taxes and transaction costs. The transaction, valued at a closing price of $50.41 per share on February 13, 2026, is linked to the exercise of share option programs.
Qiagen NV (QGEN) Shares Down 3.25% on Feb 17
Qiagen NV (QGEN) shares dropped 3.25% on February 17, trading at $48.77. This places the stock significantly below its 52-week high but above its 52-week low. Analysts forecast an average target price of $54.33, implying an 11.39% upside, with a consensus "Hold" recommendation.
Qiagen N.V. (NYSE:QGEN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Qiagen's stock has risen by 9.0% over the last three months, yet its fundamentals, particularly its 11% return on equity (ROE), appear to be a concern, although it aligns with the industry average. Despite retaining a significant portion of its earnings, the company has experienced a 14% decline in net income over five years. Analysts, however, predict a future drop in the payout ratio and an increase in ROE to 14%, suggesting potential improvements in earnings growth.
Qiagen’s Greener Lab Automation Push And What It Could Mean For Growth
Qiagen has launched new sustainability-focused consumables and automated sample preparation systems (QIAsprint Connect, QIAsymphony Connect, QIAmini) aimed at clinical laboratories. These initiatives address the growing demand for higher testing volumes and resource efficiency while promoting greener lab workflows. The company anticipates these offerings will drive recurring revenue and support its target of at least 5% constant currency net sales growth in 2026, though their success hinges on lab adoption and competitive differentiation.
UBS Maintains Qiagen NV(QGEN.US) With Hold Rating, Announces Target Price $52
UBS analyst Dan Leonard has maintained a "Hold" rating on Qiagen NV (QGEN.US) and set a target price of $52. According to TipRanks data, the analyst has a 58.2% success rate and an average return of 11.6% over the past year. The information provided is for informational purposes only and does not constitute investment advice.
Qiagen N.V. (NYSE:QGEN) Given Average Rating of "Hold" by Analysts
Analysts have given Qiagen N.V. (NYSE:QGEN) an average "Hold" rating, with a consensus 12-month target price of approximately $55.20. The company recently surpassed fiscal Q earnings expectations and institutional investors hold about 70% of its shares. Several analysts have adjusted their price targets and ratings on QGEN, reflecting varied perspectives on its short-term potential.
BlackRock Lifts Stake in Qiagen to Over 10% Capital Interest
BlackRock, Inc. has increased its stake in Qiagen (QGEN) to a combined direct and potential position of 10.75% capital interest and 11.89% voting rights. This significant accumulation by various BlackRock affiliated asset management entities highlights Qiagen's appeal to large institutional investors and is expected to strengthen liquidity and governance engagement for the stock. An analyst currently rates QGEN as a Hold with a $52.00 price target.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. announced a release under Article 40, Section 1 of the WpHG, detailing a notification from the AFM regarding Goldman Sachs Group Inc.'s holdings in QIAGEN N.V. The notification, dated February 11, 2026, includes details of transactions from February 6, 2026, showing Goldman Sachs' direct and indirect holdings of QIAGEN shares, call options, convertible bonds, warrants, and swaps, totaling 3.42% in capital interest and voting rights. QIAGEN N.V. clarified that it is not responsible for the accuracy of the notification, having taken it directly from the AFM's register.
BlackRock Lifts Stake in Qiagen to Over 10% Capital Interest
BlackRock has increased its stake in Qiagen, with Dutch regulators disclosing that BlackRock now holds over 10% of Qiagen's capital interest. Through various affiliated asset managers, BlackRock controls 11.89% of Qiagen's voting rights and has a total capital interest of 10.75%. This move highlights Qiagen's attractiveness to large institutional investors and could enhance the stock's liquidity and governance engagement.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a notification regarding voting rights, as advised by the Netherlands Authority For the Financial Markets (AFM) on February 11, 2026. The notification details a transaction on February 6, 2026, involving Goldman Sachs Group Inc., The, and outlines their distribution of shares, call-options, convertible bonds, warrants, and swaps in both real and potential capital interests. Goldman Sachs Group Inc., The holds a total of 3.42% in both capital interest and voting rights, with specific breakdowns provided for direct and indirect holdings.
Qiagen Automation Push And Sustainability Aims Meet Undervalued Stock Story
Qiagen (NYSE:QGEN) has introduced new automation platforms for DNA and RNA extraction, emphasizing sustainability with products like QIAsprint Connect, QIAsymphony Connect, and QIAmini. The company, currently trading below its fair value and analyst targets, is focusing on these innovations to strengthen its position in clinical and research laboratories. While showing positive recent momentum, investors should monitor the adoption of these new platforms and consider the risk that the dividend yield is not well covered by free cash flows, especially if investment in automation increases.
UBS Adjusts QIAGEN Price Target to $52 From $50, Maintains Neutral Rating
UBS has increased its price target for QIAGEN (QGEN) to $52 from $50, while reiterating a Neutral rating on the stock. This adjustment reflects an updated outlook on the company, though the investment bank maintains its hold recommendation. The article also includes various news items and financial updates related to QIAGEN N.V., indicating recent positive financial performance and analyst sentiment.
Qiagen N.V. $QGEN Shares Sold by Nuance Investments LLC
Nuance Investments LLC significantly reduced its stake in Qiagen N.V. (NYSE:QGEN) by 60.3% in Q3, selling over 800,000 shares. Despite this, other institutional investors have increased their holdings, and major institutional ownership stands at 70%. Qiagen's Q4 results surpassed revenue and EPS estimates, though management's FY2026 and Q1 guidance was below expectations, leading to mixed analyst ratings for the company.
Qiagen targets 9% growth in 2026 growth pillars and $2B by 2028 with new product launches
This article mentions that Qiagen is targeting a 9% growth rate by 2026 for its growth pillars and aims to achieve $2 billion in revenue by 2028. This growth is expected to be driven by new product launches.
Qiagen N.V. (NYSE:QGEN) Q4 2025 Earnings Call Transcript
QIAGEN N.V. (NYSE:QGEN) reported strong Q4 and full-year 2025 results, exceeding their financial outlook for both sales and adjusted earnings per share. The company's growth pillars, including Sample technologies, QuantiFERON, QIAstat, QIAcuity, and QIAGEN Digital Insights, achieved significant sales growth and are on track to meet their 2028 targets. QIAGEN also detailed strategic investments, new product launches, and continued capital returns to shareholders, while providing a cautious but optimistic outlook for 2026 amid ongoing macroeconomic uncertainties.
Qiagen (QGEN) PT Raised by JP Morgan Amid Overweight Rating | QG
JP Morgan has increased its price target for Qiagen (QGEN) to $60.00 from $55.00, reiterating an Overweight rating. This upward adjustment reflects a positive outlook from the firm, indicating anticipated growth potential for the company. Other analysts have also adjusted their ratings and price targets for QGEN in recent months, showcasing varied perspectives on its future prospects.
Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, based on a notification from the AFM dated February 5, 2026. The disclosure details DWS Investment GmbH's indirect holdings in QIAGEN N.V. as of February 3, 2026, showing a capital interest and voting rights of 1.63% and 3.05% respectively. QIAGEN N.V. emphasizes it is not responsible for the accuracy of the provided notification.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released a voting rights announcement according to Article 40, Section 1 of the WpHG. The notification, issued by the AFM, indicates that DWS Investment GmbH has disclosed a notification related to QIAGEN N.V., with a capital interest of 1.63% and voting rights of 3.05%. The transaction date was February 3, 2026.
Stifel raises Qiagen stock price target to $50 on growth outlook
Stifel increased its price target for Qiagen NV (NYSE:QGEN) to $50.00 from $45.00 while maintaining a Hold rating, noting the company is currently undervalued according to InvestingPro data. Qiagen's first-quarter guidance was below consensus, but Stifel projects approximately 3% organic growth for FY2026, with acceleration in the second half. The stock's performance is expected to be largely influenced by takeover speculation, despite its "GREAT" financial health and aggressive share buybacks.
Qiagen NV (QGEN) PT Raised to $50 at Stifel
Stifel analyst Daniel Arias recently raised the price target for Qiagen NV (QGEN) to $50. This update indicates a positive outlook from Stifel regarding the company's stock performance. The article notes that further details are available to premium subscribers.
QGEN's Q4 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down
QIAGEN N.V. (QGEN) reported Q4 2025 adjusted earnings of 62 cents per share, meeting analyst estimates, with revenues up 3.7% year over year to $540.4 million, exceeding expectations. Despite the positive revenue figures, the company's stock dipped 0.9% following the announcement. For 2026, QIAGEN projects net sales to increase about 5% CER and adjusted EPS of at least $2.50.
QIAGEN (NYSE: QGEN) tops 2025 targets and guides for at least 5% CER sales growth in 2026
QIAGEN N.V. (NYSE: QGEN) exceeded its 2025 financial targets, reporting $2.09 billion in net sales with 5% CER growth and adjusted diluted EPS of $2.40 CER. The company's growth pillars achieved significant sales, contributing to an improved adjusted operating margin despite external pressures. For 2026, QIAGEN forecasts at least 5% CER sales growth and adjusted diluted EPS of at least $2.50 CER, driven by continued investment in its core portfolio and strategic acquisitions.
Jefferies Maintains Buy on Qiagen N.V. (QGEN) Feb 2026
Jefferies has reiterated its "Buy" rating for Qiagen N.V. (QGEN) and raised its price target from $57 to $59 as of February 5, 2026. This action reflects the firm's continued confidence in Qiagen’s diagnostic franchise and steady revenue streams. Meyka AI also assigns QGEN a B+ grade, considering factors like S&P 500 comparison, sector performance, and financial growth, suggesting a positive outlook for the company.
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
QIAGEN N.V. announced strong financial results for Q4 and full-year 2025, surpassing its sales and adjusted EPS outlooks. The company's growth pillars achieved combined sales of $1.49 billion CER with 8% CER growth, contributing to net sales of $2.09 billion for the full year. QIAGEN also provided a positive outlook for 2026, forecasting continued growth and increased adjusted diluted EPS.
Investors Purchase Large Volume of Call Options on Qiagen (NYSE:QGEN)
Investors purchased 40,639 call options on Qiagen (NYSE:QGEN), an increase of 4,664% compared to the typical daily volume, signaling significant bullish interest. This unusual activity follows Qiagen beating Q4 earnings estimates but cutting Q1 and FY2026 EPS guidance below Street expectations. The company anticipates at least 5% sales growth for 2026 and introduced a new high-throughput system, QIAsprint Connect, as a potential long-term growth driver despite near-term profit caution.
Allianz Asset Management GmbH Purchases 534,527 Shares of Qiagen N.V. $QGEN
Allianz Asset Management GmbH significantly increased its stake in Qiagen N.V. by 53.7% in Q3, acquiring 534,527 additional shares to hold a total of 1,529,224 shares valued at $68.0 million. This increase makes Allianz Asset Management GmbH one of the largest institutional holders of Qiagen stock, owning approximately 0.69% of the company. Despite beating Q4 EPS estimates, Qiagen's stock has faced pressure due to management's lower-than-consensus Q1 and full-year 2026 EPS guidance.
QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars
QIAGEN N.V. (NYSE: QGEN) announced strong financial results for Q4 and full-year 2025, surpassing its sales and adjusted EPS outlooks. The company reported Q4 net sales of $540 million and full-year net sales of $2.09 billion, driven by robust performance in its growth pillars. QIAGEN also provided an optimistic outlook for 2026, projecting at least 5% CER net sales growth and adjusted diluted EPS of at least $2.50 CER.
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. has released an announcement regarding a voting rights notification received from the AFM (the Netherlands Authority For the Financial Markets). The notification, dated February 03, 2026, concerns BlackRock, Inc.'s holdings in QIAGEN N.V., detailing both real and potential capital interests and voting rights through various indirect entities and financial instruments like Ordinary Shares and Contracts for Difference. BlackRock's total capital interest is reported at 10.79% and voting rights at 11.95%.
Goldman Sachs Reports 3.11% Stake in QIAGEN via Shares and Derivatives
Goldman Sachs Group Inc. has disclosed a 3.11% stake in QIAGEN (QGEN) as of January 28, 2026, through a combination of shares and various financial instruments. This significant holding by a major institutional investor like Goldman Sachs highlights ongoing interest in QIAGEN's stock and could influence its market perception and liquidity. Currently, analysts have a "Buy" rating on QGEN with a target price of $60.00.
BlackRock Discloses Significant Stake in QIAGEN
QIAGEN has announced that BlackRock, Inc. now holds a significant stake in the company, with a total capital interest of 10.79% and voting rights of 11.95% as of January 29, 2026. This substantial holding was disclosed to QIAGEN by the Dutch financial markets regulator AFM. The announcement highlights BlackRock's considerable influence in QIAGEN's shareholder base and could enhance the company's visibility in international capital markets.
Qiagen guides to at least 5% sales growth in 2026
Qiagen NV released its fourth-quarter earnings report, showing adjusted per-share profit of 62 cents and sales of $540 million, driven by strong growth in tuberculosis testing and diagnostics. For 2026, the company forecasts net sales growth of at least 5% at constant exchange rates and adjusted EPS of at least $2.50. Despite a slowdown in Q4 due to U.S. tariffs and higher marketing costs, Qiagen remains on track to meet its 2028 targets.
QIAGEN beats 2025 goals, returns $1.1B and sets higher 2026 EPS bar
QIAGEN announced strong Q4 and full-year 2025 results, exceeding its outlook for sales and adjusted EPS. The company reported net sales of $540 million for Q4 and $2.09 billion for the full year, driven by its growth pillars. QIAGEN also returned over $1.1 billion to shareholders ahead of schedule and set an optimistic outlook for 2026 with expected net sales growth of at least 5% CER and adjusted diluted EPS of at least $2.50 CER.
Qiagen faces earnings test as analyst estimates slide 15% despite takeover chatter
Qiagen is facing an earnings test as analyst estimates for its fourth-quarter results have slid 15% despite ongoing takeover chatter. The life sciences and diagnostics company is expected to report flat earnings year-over-year, and analysts have expressed skepticism, leading to recent downgrades. Investors will be keenly watching the company's ability to provide positive guidance, address concerns about margin and cost pressures, and offer updates on potential strategic options including a sale.
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
QIAGEN introduced its new QIAsprint Connect high-throughput automation system at SLAS 2026, marking its entry into advanced benchtop sample processing for research labs. This system aims to provide efficiency, flexibility, and sustainability by processing up to 192 samples per run with reduced plastic waste. QIAGEN also unveiled QIAsymphony Connect for clinical applications and QIAmini for low-throughput labs, reinforcing its commitment to scalable automation across diverse laboratory needs.
QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026
QIAGEN announced the public showcase of its new QIAsprint Connect high-throughput automation system at SLAS 2026, designed for efficient and sustainable sample processing in research laboratories. The company also plans to introduce QIAsymphony Connect for clinical applications and QIAmini for low-throughput labs, expanding its automation portfolio to meet diverse laboratory needs. These systems aim to provide scalable, flexible, and environmentally conscious solutions for sample preparation.
BlackRock Discloses Significant Stake in QIAGEN
BlackRock, Inc. has disclosed a significant holding in QIAGEN, with a total capital interest of 10.79% and voting rights of 11.95% as of January 29, 2026. This stake, held through various BlackRock entities via shares and derivatives, was reported by the Dutch financial markets regulator AFM. The announcement highlights QIAGEN's attractiveness to major global investors and strengthens its international capital market profile.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
QIAGEN N.V. announced a release according to Article 40, Section 1 of the WpHG, based on a notification from the AFM dated February 3, 2026. The notification details transactions by Goldman Sachs Group Inc. on January 28, 2026, involving various types of shares and financial instruments in QIAGEN N.V. The reported capital interest and voting rights for Goldman Sachs Group Inc. (indirectly) stand at 3.11%.
New QIAGEN robot handles 192 lab samples per run automatically
QIAGEN has introduced QIAsprint Connect, a new high-throughput benchtop automation system designed for processing up to 192 lab samples per run efficiently and with reduced environmental impact. The company also showcased QIAsymphony Connect for clinical applications and QIAmini for accessible low-throughput sample processing, highlighting its commitment to scalable automation for laboratories worldwide. These new systems prioritize flexibility, sustainability, and data compliance, aiming to meet the growing demands of research and clinical labs.
Strs Ohio Sells 33,555 Shares of Qiagen N.V. $QGEN
Strs Ohio significantly reduced its stake in Qiagen N.V. by 86.8% in Q3, selling over 33,000 shares and retaining a smaller position valued at $228,000. This move aligns with a broader cautious sentiment among analysts, who have largely shifted to "Hold" ratings for Qiagen, setting a consensus target price of $53.04. Despite the institutional selling and analyst downgrades, Qiagen recently surpassed quarterly EPS and revenue estimates, with its shares trading within a 52-week range of $39.61–$57.81 and holding a market capitalization of approximately $11.02 billion.
€43.77 Qiagen (QIA.DE XETRA) intraday 03 Feb 2026 ahead of earnings: what to watch
This article provides an in-depth analysis of Qiagen (QIA.DE) stock ahead of its earnings report on February 4, 2026. It highlights key financials, valuation metrics, Meyka AI's forecast (B+ rating, BUY suggestion, but projecting a yearly price of €40.22), and potential risks and catalysts. Investors are advised to focus on revenue drivers, margins, cash flow, and guidance commentary in the upcoming report.
Goldman Sachs Discloses 3.26% Voting Interest in QIAGEN
Goldman Sachs has revealed a 3.26% capital and voting interest in QIAGEN, held through various entities and a mix of financial instruments. This disclosure, notified by the Dutch financial markets regulator AFM, indicates strong institutional interest in QIAGEN's equity. Despite the company's note that it's not responsible for the AFM data's accuracy, the announcement highlights a significant position by a major global financial institution.
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG
This article reports on a voting rights announcement for QIAGEN N.V. as released by the AFM (Netherlands Authority For the Financial Markets). Goldman Sachs Group Inc., The, notified the AFM on January 30, 2026, regarding their holdings in QIAGEN N.V., detailing various types of shares, swaps, convertible bonds, and options, resulting in a total capital interest and voting rights of 3.26%.
Qiagen N.V. (QGEN) Stock Analysis: Diagnostic Powerhouse With A 6.1% Revenue Growth
Qiagen N.V. (QGEN) is a healthcare diagnostic and research company with a market cap of $11.06 billion, demonstrating resilience and a 6.10% revenue growth. The company maintains a strong financial position with a 11.29% return on equity and $667 million in free cash flow, prioritizing growth and innovation. Analyst sentiment is cautiously optimistic, and technical indicators suggest a potential buying opportunity due to the stock being in oversold territory.
Barclays Maintains Qiagen NV(QGEN.US) With Buy Rating, Cuts Target Price to $55
Barclays analyst Luke Sergott has reiterated a Buy rating on Qiagen NV (QGEN.US) but has adjusted the target price downwards from $57.89 to $55. Sergott's track record, according to TipRanks, shows a 45.6% success rate and a negative average return of -0.2% over the past year. TipRanks provides independent analysis of financial analysts' recommendations, including success rates and average returns, noting that this information is for informational purposes only and not investment advice.
